Literature DB >> 10708304

Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP).

T J Tewson1, D A Mankoff, L M Peterson, I Woo, P Petra.   

Abstract

Fluorine-18 16alpha-Fluoroestradiol ([18F]-FES) is a positron-emitting tracer for the estrogen receptor that is used for positron emission tomography (PET) studies of tumor tissues rich in the estrogen receptor. The role of the sex steroid binding protein (SBP or SHBG) in the transport of the [18F]-FES to the estrogen-receptor-rich tissue in breast cancer patients in vivo was investigated. To determine the extent to which [18F]-FES is bound to SBP in the blood, we performed a series of studies using blood samples obtained from patients undergoing [18F]-FES PET scans. The binding of [18F]-FES to the SBP was measured using a simple protein precipitation assay. The binding of [18F]-FES metabolites to SBP was also measured. These measurements showed that the tracer was distributed between albumin and SBP, and the binding capacity of SBP was sufficient to ensure that the protein was not saturated when the tracer was fully mixed with the plasma; however, local saturation of SBP may occur when [18F]-FES is administered intravenously. Typically about 45% of [18F]-FES in circulating plasma was bound to SBP, but this fraction was dependent on the concentration of SBP in plasma. The transfer of the tracer between the two proteins was rapid, complete in less than 20 s at 0 degrees C, suggesting that the equilibrium was maintained under most circumstances and that local saturation resolved quickly when blood from the injection site entered the central circulation. These data suggest that SBP binding of [18F]-FES is significant and will affect the input function of the tracer for any model that is used for the quantitative evaluation of [18F]-FES uptake in PET studies. Estimates of equilibrium binding in blood samples are sufficient to characterize [18F]-FES binding to SBP in the circulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10708304     DOI: 10.1016/s0969-8051(99)00072-4

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  11 in total

Review 1.  Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Authors:  D A Mankoff; F Dehdashti; A F Shields
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.

Authors:  Lanell M Peterson; Brenda F Kurland; Jeanne M Link; Erin K Schubert; Svetlana Stekhova; Hannah M Linden; David A Mankoff
Journal:  Nucl Med Biol       Date:  2011-05-05       Impact factor: 2.408

Review 3.  Development of Companion Diagnostics.

Authors:  David A Mankoff; Christine E Edmonds; Michael D Farwell; Daniel A Pryma
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

4.  Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Authors:  Michel Paquette; Éric Lavallée; Serge Phoenix; René Ouellet; Helena Senta; Johan E van Lier; Brigitte Guérin; Roger Lecomte; Éric E Turcotte
Journal:  J Nucl Med       Date:  2017-08-10       Impact factor: 10.057

Review 5.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

Review 6.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

7.  Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.

Authors:  Erin Currin; Hannah M Linden; David A Mankoff
Journal:  Curr Breast Cancer Rep       Date:  2011-12

Review 8.  Advances in molecular imaging for breast cancer detection and characterization.

Authors:  Jennifer M Specht; David A Mankoff
Journal:  Breast Cancer Res       Date:  2012-03-16       Impact factor: 6.466

Review 9.  The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors:  John A Katzenellenbogen
Journal:  Nucl Med Biol       Date:  2020-02-22       Impact factor: 2.408

Review 10.  Molecular imaging as a tool for translating breast cancer science.

Authors:  David A Mankoff
Journal:  Breast Cancer Res       Date:  2008-12-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.